Qubigen Collaborates with Dr. Srinivas Viswanathan at Dana-Farber Cancer Institute on Novel Kidney Cancer Research
- May 11
- 2 min read
Qubigen is pleased to report on a research collaboration with Dr. Srinivas Viswanathan and his team at Dana-Farber Cancer Institute. The project focuses on the discovery of novel small-molecule candidates for a rare and aggressive type of kidney cancer.
Computational Modeling and Federated AI Powered Design
Using Qubigen’s privacy-preserving Federated AI platform, we have applied advanced computational modeling to identify and rank potential compounds that may disrupt key oncogenic mechanisms in this disease.
Initial results from the computational phase have been encouraging. Several candidate molecules showed promising binding characteristics in modelling studies, and these early hits are now advancing for further biological investigation, functional testing, and improvement.
Dr. Viswanathan commented:
“We are excited to partner with Qubigen’s AI platform to explore new therapeutic avenues for this rare and aggressive form of kidney cancer. Early computational insights have been encouraging and we look forward to advancing these candidates further.”
This collaboration highlights how privacy-first AI might accelerate early-stage discovery while fully respecting data security and institutional control - core principles of Qubigen’s approach.
Initial experimental results are instrumental at guiding Federated AI toward high potency and selective compounds. With hints toward the more effective mechanisms of action, privacy-preserving AI can leverage insights without moving or exposing any data from the collaboration.
We look forward to continuing our work with Dr. Viswanathan and the Dana-Farber team as these promising early results progress toward the next stage of evaluation for this important therapeutic area.
Qubigen - Accelerate Drug Design Without Exposing Secrets
Qubigen builds and hosts powerful, privacy-preserving AI Engines, turning discrete client-specific data into a competitive edge.
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure Federated AI and quantum chemistry platform can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
